Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Luckily for you, our mission at StockStory is to help you make money and avoid losses by sorting the winners from the losers. Keeping that in mind, here is one small-cap stock that could be the next 100 bagger and two best left ignored.
Two Small-Cap Stocks to Sell:
Tandem Diabetes (TNDM)
Market Cap: $1.36 billion
With technology that automatically adjusts insulin delivery based on continuous glucose monitoring data, Tandem Diabetes Care (NASDAQ: TNDM) develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels.
Why Do We Pass on TNDM?
- Weak pump shipments over the past two years imply it may need to invest in improvements to get back on track
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
- EBITDA losses may force it to accept punitive lending terms or high-cost debt
At $20.09 per share, Tandem Diabetes trades at 29x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why TNDM doesn’t pass our bar.
AdaptHealth (AHCO)
Market Cap: $1.34 billion
With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ: AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders.
Why Does AHCO Fall Short?
- Annual revenue growth of 2.1% over the last two years was below our standards for the healthcare sector
- Issuance of new shares over the last five years caused its earnings per share to fall by 1.3% annually while its revenue grew
- Low returns on capital reflect management’s struggle to allocate funds effectively, and its shrinking returns suggest its past profit sources are losing steam
AdaptHealth’s stock price of $10.02 implies a valuation ratio of 11.7x forward P/E. Dive into our free research report to see why there are better opportunities than AHCO.
One Small-Cap Stock to Watch:
iRhythm (IRTC)
Market Cap: $5.02 billion
Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies (NASDAQ: IRTC) provides wearable cardiac monitoring devices and AI-powered analysis services that help physicians detect and diagnose heart rhythm disorders.
Why Does IRTC Stand Out?
- Annual revenue growth of 23.4% over the last five years was superb and indicates its market share increased during this cycle
- Adjusted operating profits and efficiency rose over the last five years as it benefited from some fixed cost leverage
- Free cash flow flipped to positive over the last five years, showing the company is at an important crossroads
iRhythm is trading at $155.88 per share, or 57.3x forward EV-to-EBITDA. Is now a good time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.
Don’t wait for the next volatility shock. Check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
